2-(fluoromethyl)-4-methylpyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-(fluoromethyl)-4-methylpyridine
• 英文别名: 2-(Fluoromethyl)-4-methylpyridine
• 化学式: C₇H₈FN
• 分子量: 125.146
• InChiKey: JRTCGYOANYBWNG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2,4-二甲基吡啶 在 碳酸氢钠 、 Selectfluor 作用下， 以 乙腈 为溶剂， 反应 20.0h， 以24%的产率得到2-(fluoromethyl)-4-methylpyridine
  参考文献：
  名称：

  Direct and Regioselective C(sp3)–H Bond Fluorination of 2-Alkylazaarenes with Selectfluor

  摘要：

  标题：摘要 在这里，我们开发了一种选择性和直接的吡啶基和喹啉基C(sp3)–H键单氟化策略，无需过渡金属条件，使用Selectfluor。该反应在温和条件下进行，并以中等至良好的产率得到氟代氮杂环化合物，包括2-甲基吡啶和喹啉。

  DOI：

  10.1055/s-0040-1706482

文献信息

• PHTHALAZINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS
  申请人：Vu Chi B.

  公开号：US20130190309A1

  公开（公告）日：2013-07-25

  Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了新颖的调节sirtuin的化合物及其使用方法。这些调节sirtuin的化合物可用于延长细胞的寿命，并治疗和/或预防各种疾病和疾病，包括与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块疾病、炎症、癌症、潮红以及那些会受益于增加线粒体活性的疾病或疾病。还提供了包含sirtuin调节化合物与另一种治疗剂结合的组合物。
• PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US20140213585A1

  公开（公告）日：2014-07-31

  This invention is directed to methods of treating diseases or conditions associated with JAK2 activity in a mammal comprising the administration of a compound of formula (I): where n, m, Y, R 1 , R 2 , R 3 , R 4 and R 5 are disclosed herein, or a pharmaceutically acceptable salt.

  本发明涉及用于治疗哺乳动物中与JAK2活性相关疾病或病症的方法，包括给予以下公式（I）的化合物或其药学上可接受的盐：其中n，m，Y，R1，R2，R3，R4和R5在此被披露。
• HETEROARYL DERIVATIVES AS CFTR MODULATORS
  申请人：Ventex Pharmaceuticals Incorporated

  公开号：US20150265612A1

  公开（公告）日：2015-09-24

  The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTC”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

  本发明涉及ATP结合盒（“ABC”）转运蛋白或其片段的调节剂，包括囊性纤维化跨膜传导调节因子（“CFTC”），以及其组合物和使用这些调节剂的方法。本发明还涉及使用这些调节剂治疗ABC转运蛋白介导的疾病的方法。
• 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US20160115169A1

  公开（公告）日：2016-04-28

  The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.

  本发明涉及一种新型的6,7-二氢吡唑并[1,5-a]吡嗪-4(5H)-酮衍生物，作为代谢型谷氨酸受体亚型2（“mGluR2”）的负向变构调节剂（NAMs）。本发明还涉及包含这些化合物的制药组合物、制备这些化合物和组合物的方法，以及使用这些化合物和组合物预防或治疗与代谢型受体亚型2有关的疾病。
• HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS
  申请人：Sun Robert

  公开号：US20110038876A1

  公开（公告）日：2011-02-17

  Disclosed are the ERK inhibitors of formula 1.0: [Formula (1.0)] and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

  本发明涉及公开的ERK抑制剂，其化学式为1.0：[Formula (1.0)]及其药学上可接受的盐、酯和溶剂化物。其中，Q是一个可具有桥或融合环的哌啶或哌嗪环。哌啶环中可以在环中具有双键。所有其他取代基均如所定义。本发明还公开了使用化合物1.0治疗癌症的方法。